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Abstract
Introduction: Differential patterns of brain atrophy on structural magnetic resonance imaging 
(MRI) revealed four reproducible subtypes of Alzheimer’s disease (AD): (1) “typical”, (2) 
“limbic-predominant”, (3) “hippocampal-sparing”, and (4) “mild atrophy”. We examined the 
neurobiological characteristics and clinical progression of these atrophy-defined subtypes.
Methods: The four subtypes were replicated using a clustering method on MRI data in 260 
amyloid-β-positive patients with mild cognitive impairment or AD dementia, and we subsequently 
tested whether the subtypes differed on [18F]flortaucipir (tau) positron emission tomography, 
white matter hyperintensity burden, and rate of global cognitive decline.
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Results: Voxel-wise and region-of-interest analyses revealed the greatest neocortical tau load in 
hippocampal-sparing (frontoparietal-predominant) and typical (temporal-predominant) patients, 
while limbic-predominant patients showed particularly high entorhinal tau. Typical patients with 
AD had the most pronounced white matter hyperintensity load, and hippocampal-sparing patients 
showed the most rapid global cognitive decline.
Discussion: Our data suggest that structural MRI can be used to identify biologically and 
clinically meaningful subtypes of AD.
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1. Introduction
Various structural neuroimaging approaches have been used to identify subtypes of 
Alzheimer’s disease (AD) based on patterns of regional atrophy [1–4]. These studies 
identified reproducible AD subtypes, namely “limbic-predominant”, “hippocampal-sparing”, 
“typical” (i.e., a combination of limbic-predominant and hippocampal-sparing) AD, and, to 
a lesser extent, “mild atrophy” AD [5]. These AD subtypes showed robust associations with 
age, APOE ε4 status, and clinical phenotype [6]. However, the neurobiological features 
underlying AD subtypes are largely unknown and cannot be explained by amyloid-β (Aβ) 
pathology because the distribution of Aβ positron emission tomography (PET) retention is 
virtually the same across AD phenotypes [7]. Capturing this heterogeneity is important 
because it could enhance our understanding of disease mechanisms, it may improve 
diagnosis and prognosis, and distinct subtypes might respond differently to future disease-
modifying treatments. We therefore aimed to test whether tau PET patterns or white matter 
hyperintensities (WMH) on MRI are associated with distinct atrophy patterns across 260 Aβ
+ patients with AD to better understand the disease pathologies underlying this 
heterogeneity in regional neurodegeneration.
2. Methods
2.1. Participants
We included 260 patients from the Memory Disorder Clinic of Gangnam Severance Hospital 
(Seoul, South Korea), the Swedish BioFINDER study (www.biofinder.se) at Lund 
University (Lund, Sweden), and the University of California San Francisco (UCSF) AD 
Research Center (San Francisco, USA) who underwent [18F]flortaucipir PET between June 
2014 and November 2017. All patients were Aβ+ by PET and/or cerebrospinal fluid (see our 
previous report for details [8]), 83 had mild cognitive impairment (MCI [9]), and 177 had 
AD dementia [10]. All underwent a medical history and complete neurological examination, 
brain MRI, and neuropsychological testing. Informed consent was obtained from all 
participants, and local institutional review boards for human research approved the study.
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2.2. Acquisition of PET and MRI data
PET images were acquired using a Biograph mCT PET/computed tomography scanner 
(Siemens Medical Solutions) in Seoul, Discovery 690 PET scanner (GE medical systems) in 
BioFINDER, a Biograph 6 Truepoint PET/computed tomography scanner (Siemens Medical 
Solutions) at Lawrence Berkeley National Laboratory for UCSF patients, after a bolus 
injection of ~370 MBq (BioFINDER and UCSF) or ~280 MBq (Seoul) of [18F]flortaucipir. 
PET data were locally reconstructed into 4 × 5-minute frames for the 80- to 100-min interval 
after injection [11–13]. MRI scans were acquired at 3T on a Discovery MR750 scanner (GE 
medical systems) in Seoul, 3.0T Tim Trio or Skyra scanner (Siemens Medical Solutions) in 
BioFINDER, and a 3.0T Tim Trio or Prisma scanner (Siemens Medical Solutions) at UCSF.
2.3. T1-weighted MRI processing
MRI data were centrally processed (at Lund University), using previously reported 
procedures [8]. Briefly, cortical reconstruction and volumetric segmentation were performed 
with the FreeSurfer image analyses pipeline version 6.0. T1-weighted images underwent 
correction for intensity homogeneity, removal of nonbrain tissue, and segmentation into gray 
matter and white matter. Reconstructed data sets were visually inspected for accuracy, and 
segmentation errors were corrected.
2.4. [18F]Flortaucipir PET processing
PET images were first resampled to obtain the same image size (128 × 128 × 63 matrix) and 
voxel dimensions (2.0 × 2.0 × 2.0 mm) across centers. Then, PET images were centrally 
processed (at Lund University) by previously reported procedures [8]. [18F]Flortaucipir 
images were motion-corrected using Analysis of Functional NeuroImages’s 3dvolreg, time-
averaged, and rigidly coregistered to the skull-stripped MRI scan. Voxel-wise standardized 
uptake value ratio (SUVR) images were created using inferior cerebellar gray matter as the 
reference region [14]. FreeSurfer (version 6.0, http://surfer.nmr.harvard.edu/) parcellation of 
the T1-weighted MRI scan was applied to the PET data transformed to subjects’ native T1-
space to extract mean regional SUVR values for each participant. We calculated mean [18F] 
flortaucipir SUVR in seven predefined regions of interest (ROIs) including entorhinal cortex, 
lateral temporal cortex, medial and lateral parietal cortex, occipital cortex frontal cortex, and 
whole-cortex. Detailed composition of each ROI by FreeSurfer label can be found in 
Supplementary Table 1. In addition, we performed partial volume correction (PVC) using 
the Geometric Transfer Matrix approach [15]. We report both PVC (main report) and non-
PVC (Supplementary Material) ROI results. For voxel-wise analyses, [18F]flortaucipir 
images were warped into the Montreal Neurological Institute standard space using the 
nonlinear transformation calculated by normalizing the T1-weighted MRI scan to the 
Montreal Neurological Institute 152 1 × 1 × 1 mm3 template with Advanced Normalization 
ToolS. Before voxel-wise analyses, images were smoothed with an 8-mm full width at half 
maximum Gaussian kernel [16].
2.5. Fluid Attenuated Inversion Recovery MRI processing
T2-weighted Fluid Attenuated Inversion Recovery images were available for 259 of 260 
subjects and were all manually inspected. We estimated WMH volumes following a 
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segmentation method described elsewhere [17]. This method builds a Bayesian probabilistic 
data model based on a Gaussian mixture model with evolving number of components, which 
is able to account for observation outliers and incorporates anatomical priors and contextual 
constraints. After convergence of the model, candidate lesion voxels are selected based on 
their distance to normalcy (i.e., healthy white matter), and resulting connected components 
are then automatically classified as lesion or artefacts based on their anatomical location. 
Resulting probabilistic maps are integrated over ROIs (layers and lobes) to calculate WMH 
volumes.
2.6. Clinical progression
Both retrospective and prospective longitudinal Mini-Mental State Examination (MMSE) 
scores were used to model changes in global cognition over time. We collected a total of 664 
data points from 246 patients; 276 MMSE scores were collected between −1 and +1 year to 
PET, 182 ≤ 1 year before PET and 206 ≥ 1 year after PET. Of 246 patients with MMSE data 
available, 182 had had at least two time points of data, with a median of 3 (range: 2 to 8 data 
points). The mean interval between first and last MMSE assessment was 2.0 ± 1.8 years 
across all groups and was longer for typical AD (3.2 ± 2.0 years) than that for all other 
groups (limbic-predominant: 1.7 ± 1.7 years, mild atrophy: 1.6 ± 1.4 years, hippocampal-
sparing: 1.3 ± 1.1 years, P < .001).
2.7. Procedure for determining atrophy-defined subtypes
In a previously described method [18], established visual MRI rating scales of medial 
temporal lobe atrophy (MTA), posterior atrophy (PA), and global cortical atrophy-frontal 
subscale (GCA-F) were used to determine atrophy-defined subtypes. Each visual rating scale 
score was binarized as “normal” or “abnormal” based on established clinical cut-offs [19], 
and the combination of the scales resulted in classification into distinct subtypes of AD. For 
example, abnormal MTA + normal PA/GCA-F = “limbic-predominant,” while normal MTA 
+ abnormal PA and/or GCA-F = “hippocampal-sparing.” Advantages of this method are its 
computational simplicity and relevance to clinical practice, but the nonautomated procedure 
(i.e., visual read) and dichotomous data structure (i.e., normal/abnormal) could be 
considered suboptimal. We aimed to apply a quantitative (clustering) implementation that 
preserves the simplicity and clinical utility of this method. We therefore calculated the mean 
surface area–weighted thickness of the entire occipital/parietal cortex and frontal cortex 
(resembling PA and GCA-F scales, respectively) and total intracranial volume–weighted 
hippocampal volumes (resembling MTA scale). The continuous measures for these three 
variables were entered into a two-step clustering algorithm in SPSS version 22.0 (Fig. 1A). 
In the first step, we performed a sequential clustering approach by constructing a modified 
cluster feature tree using model-based distance criterion (i.e., the decrease in log-likelihood 
when merging two clusters into one [20]). In the second step, we applied an agglomerative 
hierarchical clustering method using the preclusters from step 1 as an input [21]. As we 
aimed to reproduce the subtypes described by Ferreira et al. [18], the number of clusters was 
constrained to four. To test whether the clusters indeed resembled the expected subtypes, we 
standardized the posterior and frontal thicknesses and the hippocampal volume measures (z 
= 0 represents the mean of the entire group) and examined the relative impairment of these 
three variables for each cluster (Fig. 1B). Cluster 1 (n = 70) showed negative z-scores 
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(representing greater neurodegeneration) on all MRI measures and was labeled “typical 
AD”. Cluster 2 (n = 77) was characterized by low hippocampal volumes but relatively 
preserved posterior and frontal thicknesses, thus labeled “limbic-predominant AD”. Cluster 
3 (n = 76) showed the opposite pattern and was labeled “hippocampal-sparing AD”. Finally, 
cluster 4 (n = 37) showed relative preservation of all MRI measures and was labeled “mild 
atrophy AD”. Fig. 1C shows an exemplary MRI scan for each of the atrophy-defined AD 
subtypes.
2.8. Statistical analyses
Differences in baseline characteristics between atrophy-defined subtypes were assessed 
using analysis of variance with post hoc least squares difference tests for continuous 
variables and χ2 and Kruskal-Wallis with post hoc Mann-Whitney U-tests for categorical or 
ordinal variables. To assess the degree of cortical thickness relative to that observed in 
cognitively normal persons, we standardized cortical thickness values of the atrophy-defined 
subtypes in medial and lateral temporal cortex, medial and lateral parietal cortex, and frontal 
and occipital cortex, based on the mean and standard deviation of 160 cognitively normal 
persons (mean age: 69.1 ± 9.5, 40.6% males, mean MMSE: 28.5 ± 1.6, 31.8% Aβ+) 
recruited from the same centers as described previously [8]. Then, we assessed differences 
between the atrophy-defined subtypes on [18F]flortaucipir PET, WMH volumes and 
longitudinal change on MMSE. For [18F]flortaucipir PET, we performed voxel-wise 
contrasts between the subtypes using SPM12. Furthermore, we compared SUVRs in seven 
predefined ROIs using analysis of variance with post-hoc least-squares difference tests. For 
WMH volumes, a generalized linear model with gamma family distribution and log link was 
used to account for the skewness of the data distribution, and the statistical models were 
corrected for age, sex, and center and total intracranial volume. [18F]Flortaucipir PET ROI 
and WMH volume analyses were repeated by additionally adjusting for MMSE to account 
for potential confounding effects of disease severity. Finally, to examine clinical progression, 
we used MMSE scores as an outcome variable in linear mixed models with subtype, time, 
and subtype*time as predictors, while covarying for age, sex, and education. The models 
contained random intercept and slopes. The threshold for statistical significance was set at P 
< .05.
2.9. Data availability
Anonymized data will be shared by request from any qualified investigator for the sole 
purpose of replicating procedures and results presented in the manuscript and as long as data 
transfer is in agreement with European Union legislation on the General Data Protection 
Regulation.
3. Results
3.1. Subject characteristics
Baseline characteristics are provided in Table 1. Patients with hippocampal-sparing AD were 
younger than all other subtypes, had a lower proportion of APOE ε4 carriers than patients 
with limbic-predominant AD, and included more females than the typical AD subtype. 
Typical patients with AD had lower MMSE scores than all other subtypes. The mild atrophy 
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group included a greater proportion of patients with MCI relative to AD dementia than all 
other subtypes. Cortical thickness z-scores of the atrophy-defined subtypes relative to 
cognitively normal persons are presented in Supplementary Table 2.
3.2. [18F]Flortaucipir PET
Fig. 2A shows mean voxel-wise [18F]flortaucipir SUVR images for each of the atrophy-
defined subtypes. Voxel-wise contrasts showed that hippocampal-sparing had greater 
[18F]flortaucipir uptake in lateral temporoparietal cortex, precuneus, posterior cingulate, 
premotor cortex, and dorsolateral prefrontal cortex than in patients with mild atrophy AD, 
with a slight left-hemisphere predominance (Fig. 2B; P < .05 family-wise-error [FWE] 
corrected). Typical patients with AD had greater [18F]flortaucipir uptake than patients with 
mild atrophy AD in bilateral inferior and middle temporal cortices and left inferior parietal 
lobule (Fig. 2B; P < .05 FWE corrected). At a more liberal threshold (P < .001 uncorrected 
for multiple comparisons), patients with limbic-predominant AD showed greater 
[18F]flortaucipir uptake than patients with mild atrophy AD in medial and lateral temporal 
cortex, putamen, and medial prefrontal cortex (Fig. 2B). Patients with hippocampal-sparing 
AD had greater [18F]flortaucipir uptake than patients with limbic-predominant AD in 
temporal, parietal, and frontal cortex (left > right), but none of these effects survived FWE 
correction (data not shown). There were no significant differences for the other contrasts.
ROI analyses using PVC data (Fig. 3A) were largely in line with the voxel-wise results, as 
the highest cortical [18F]flortaucipir uptake was found in patients with hippocampal-sparing 
(especially in frontoparietal regions) and typical (mainly in lateral temporal and occipital 
cortices) AD, followed by patients with limbic-predominant and then mild atrophy AD. The 
entorhinal cortex, however, showed greater entorhinal SUVR in patients with limbic-
predominant AD than in all other subtypes (P < .05). Non-PVC data showed higher 
[18F]flortaucipir uptake in patients with limbic-predominant AD than in patients with 
hippocampal-sparing (P < .05) and, at statistical trend-level, mild atrophy (P = .055) and 
typical (P = .051) AD and showed similar results in the remaining ROIs compared with PVC 
data (Supplementary Fig. 1). Results remained essentially the same when adjusting for 
MMSE to account for potential effects of disease severity (Supplementary Table 3).
3.3. White matter hyperintensity volumes
Table 2 and Fig. 3B show the regional WMH volume loadings for each of the atrophy-
defined subtypes. Statistical analyses of lobar loading of WMH showed that typical patients 
with AD had greater temporal WMH volumes than all other subtypes and greater occipital 
WMH volumes than patients with hippocampal-sparing AD (Table 2). In terms of radially 
divided regions, the most periventricular regions appeared significantly more affected in 
typical AD than in all other subtypes (Table 2). There were no other significant differences 
between subtypes. Additional adjustment for MMSE attenuated differences in WMH 
volumes between subtypes, and the only contrast that remained significant was greater 
WMH volumes in periventricular regions in typical patients with AD than in those with 
hippocampal-sparing AD (Supplementary Table 4).
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3.4. Clinical progression
Fig. 3C shows the slopes for MMSE scores over time, estimated from linear mixed models. 
The significant interaction time3subtype (P < .05) indicates that the cognitive trajectories 
differ across atrophy-defined subtypes. The hippocampal-sparing group showed the steepest 
slope (−2.6 [standard error: 0.4] MMSE points per year, P < .001), followed by the typical 
AD group (−2.0 [0.1], P < .001) and then the limbic-predominant (−1.5 [0.2], P < .001) and 
mild atrophy (−1.5 [0.3], P = .141) AD groups.
4. Discussion
We used a clustering method to in vivo replicate neuro-pathologically established subtypes 
of AD based on atrophy in medial temporal, posterior, and frontal brain regions of 260 
patients who are Aβ-positive with prodromal AD or AD dementia and tested whether they 
differed on tau PET, WMH burden, and rate of cognitive decline. We found the greatest tau 
load in patients with hippocampal-sparing (neocortical-predominant) AD and typical 
(temporal-predominant) patients with AD, while the entorhinal cortex was especially 
implicated in the limbic-predominant group. In addition, typical patients with AD showed 
the most pronounced WMH load compared with the other subtypes. Patients with 
hippocampal-sparing AD showed the most rapid cognitive decline, followed by typical 
patients with AD. These findings suggest that structural MRI can be used to identify 
biologically and clinically meaningful subtypes of AD and that distinct tau PET patterns and 
white matter hyperintensities are associated with atrophy-defined subtypes.
A recent study used a clustering approach on entorhinal versus cortical tau PET uptake and 
showed that the resulting clusters were associated with different clinical presentations of AD 
[22]. A novelty of this study is our demonstration of distinct tau PET patterns in atrophy-
defined subtypes of AD. Although patients with hippocampal-sparing AD and typical 
patients with AD both showed tau PET uptake in AD-specific temporoparietal regions (Fig. 
2), the hippocampal-sparing subtype was characterized by a frontoparietal predominance (L 
> R), which is in line with the distribution of neurofibrillary tangle pathology found in 
postmortem studies [5], their often atypical “nonamnestic” disease presentation [23], and the 
lower frequency of APOE ε4-positivity [18]. Typical patients with AD, on the other hand, 
harbored most tau pathology in lateral temporal cortex areas. In line with earlier studies 
[24,25], they additionally had highest white matter hyperintensity volumes. Patients with 
limbic-predominant AD showed intermediate neocortical involvement but had the greatest 
uptake of all subtypes in the entorhinal cortex, corresponding to neuropathologically 
observed distribution of neurofibrillary tangle pathology [5]. The patients with relatively 
preserved gray matter (mild atrophy group) were the least affected by tau pathology. This 
group showed only subtle reductions in cortical thickness compared with cognitively normal 
persons (Supplementary Table 2) but were all Aβ+ and had objective cognitive deficits (i.e., 
MCI or AD dementia, mean MMSE: 24 ± 4). Potential explanations for this subtype include 
the possibility that this group is characterized by low cognitive resilience to brain pathology 
[26] or that pathological processes other than Aβ, tau, or atrophy are driving the clinical 
symptoms (e.g., vascular damage [other than WMH] or different proteinopathies [27]).
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Altogether, our findings highlight that tau PET patterns map well onto the expected atrophy 
distribution and clinical phenotype [22,28–31]. Both in terms of global and regional burden, 
tau and (relative) atrophy often spatially coincided, illustrated by, for example, the elevated 
entorhinal cortex tau PET signal in patients with limbic-predominant atrophy, the low tau 
PET retention in patients who only showed mild atrophy, and the neocortical predominant 
tau PET pattern in patients with pronounced reductions in cortical thickness of posterior and 
frontal cortical regions but relatively preserved hippocampal volumes. Previous studies have 
consistently indicated that the distribution and extent of Aβ load has only a marginal effect 
on neurodegeneration and cognitive decline in clinical stages of AD [32–34]. Although the 
regional effect of Aβ (all patients in this study were Aβ+) on brain atrophy could not be 
examined (some patients had only cerebrospinal fluid available and different Aβ PET tracers 
were used), it is thus unlikely that the atrophy-defined subtypes can be explained by regional 
differences in Aβ pathology. Hence, the present study supports several other studies in 
demonstrating that tau pathology is closely associated with sites of neurodegeneration 
[12,28,35,36], and it could be argued that the inherent distribution of cerebral tau pathology 
determines to a large extent the AD subtype identified on structural MRI. The contribution 
of WMH volumes to the manifestation of atrophy-defined subtypes is less clear. Although 
this study—consistently with previous studies [18,25]—showed that typical patients with 
AD had the greatest WMH volume burden, it is unknown whether this originates from 
Wallerian degeneration as a response to hyperphosphorylated tau and/or Aβ or is due to 
small vessel disease. However, based on the observation that both WHM volumes and tau 
load were most pronounced in the temporal cortex in typical AD versus the other subtypes, 
one may speculate that the observed temporal WMH lesions were primarily due to Wallerian 
degeneration [37].
Strengths of the study include the large number of Aβ+ patients with AD with tau PET, 
MRI, and MMSE available. Furthermore, we used a quantitative implementation of well-
established visual rating systems to capture a priori defined subtypes of AD. There are also 
several limitations. First, compared with other studies [1,5,18], we had an overrepresentation 
of limbic-predominant and especially hippocampal-sparing cases relative to typical patients 
with AD, possibly due to cohort effects, methodological aspects, or the relatively young 
mean age of the sample. However, group characteristics were largely in line with previous 
studies (e.g., younger age and APOE ε4 prevalence in hippocampal-sparing AD), suggesting 
that comparable subtypes were captured across studies. Second, based on the presumed 
temporal lag between tau spread and atrophy [35,38,39], the tau PET signal could have 
converged across MRI-defined subtypes and we may have underestimated actual differences 
in tau pathology. Third, we used different MRI scanners across centers. However, as our 
clustering approach was based on covariance patterns (including both relative increases and 
decreases) and not on actual differences, we argue that this had only minor effects on the 
clustering. Further outstanding issues are the possibility that some of the differences 
between subtypes are partly driven by differences in disease stage (as adjusting the WMH 
volume analyses for MMSE attenuated most of the regional differences between subtypes) 
or even that multiple subtypes are in reality on the same continuum of a single subtype. 
Longitudinal studies will be essential to further examine this. Other key topics for future 
research are to investigate the rates and distribution of brain atrophy, accumulation of tau, 
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and WMH and to test whether and how these are related to cognitive changes over time. It 
would also be important to postmortem verify the regional distribution of tau pathology that 
was observed using ante-mortem PET and to assess the extent of comorbid pathologies (e.g., 
TDP-43, α-synuclein) in the different subtypes that can currently not be detected by 
neuroimaging techniques.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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RESEARCH IN CONTEXT
1. Systematic review: Previous studies have used structural MRI to identify 
distinct subtypes of Alzheimer’s disease (AD). The underlying tau PET 
pattern of these AD subtypes is currently unknown.
2. Interpretation: Our results demonstrate distinct tau PET patterns across 
hippocampal-sparing (frontoparietal predominant), limbic-predominant 
(medial temporal lobe predominant) and typical (temporal predominant) 
atrophy-defined subtypes of AD.
3. Future directions: To evaluate the natural evolution of distinct AD subtypes in 
terms of tau PET accumulation, brain atrophy and decline in domain-specific 
cognitive functions, and test whether information on AD subtype informs 
clinicians (e.g. prognosis) or clinical trial design (e.g. selection or 
monitoring).
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Fig. 1. 
Clustering method for determining atrophy-defined subtypes of AD. We first performed a 
two-step clustering algorithm (constrained to k = 4) with hippocampal volumes, posterior 
thickness (occipital and parietal cortex combined), and frontal thickness as input (A). Then 
the continuous MRI measures were transformed to z-scores across the sample (B). This 
revealed groups with overall low z-scores (cluster 1, called “atypical AD”), low 
hippocampal volumes but preserved cortical measures (cluster 2, “limbic-predominant 
AD”), the opposite pattern (cluster 3, “hippocampal sparing AD”), and a relatively spared 
group (cluster 4, “mild atrophy AD”). (C) A coronal and axial slice for an exemplary case 
from each of the four atrophy-defined subtypes. Abbreviations: AD, Alzheimer’s disease; 
MRI, magnetic resonance imaging.
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Fig. 2. 
[18F]Flortaucipir uptake patterns by atrophy-defined subtypes of Alzheimer’s disease. (A) 
Mean voxel-wise [18F]flortaucipir SUVR images for the four atrophy-defined subtypes of 
Alzheimer’s disease. (B) Voxel-wise contrast between hippocampal-sparing AD (left), 
typical AD (middle), and limbic-predominant AD (right) versus patients with mild atrophy 
AD. Abbreviations: AD, Alzheimer’s disease; FWE, family-wise error; SUVR, standardized 
uptake value ratio.
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Fig. 3. 
Tau PET, white matter hyperintensity volumes, and clinical progression by atrophy-defined 
subtypes of Alzheimer’s disease. (A) Partial volume–corrected [18F]flortaucipir SUVRs in 
seven predefined regions-of-interest for the four atrophy-defined subtypes of Alzheimer’s 
disease. Entorhinal cortex: Limbic-predominant > HC-sparing, P < .001; Limbic-
predominant > Typical & Mild, P < .05. Lateral temporal cortex: HC-sparing > Mild, P < .
001; HC-sparing > Limbic-predominant, P < .05; Typical > Mild & Limbic-predominant, P 
< .001; Limbic-predominant > mild, P < .05. Medial parietal cortex: HC-sparing > Mild, P 
< .001; HC-sparing > Limbic-predominant, P < .01; Typical > Mild, P < .001; Limbic-
predominant > mild, P < .05. Lateral parietal cortex: HC-sparing > Mild, & Limbic-
predominant, P < .001; Typical > Mild, P < .001; Typical > Limbic-predominant, P < .01. 
Occipital cortex: HC-sparing > Mild, P < .01; HC-sparing > Limbic-predominant, P < .05; 
Typical > Mild & Limbic-predominant, P < .01. Frontal cortex: HC-sparing > Mild, P < .
001; Typical > Mild, P < .001; Limbic-predominant > Mild, P < .05. Whole-cortex: HC-
sparing > Mild, P < .001; HC-sparing > Limbic-predominant, P < .01; Typical > Mild, P < .
001; Typical > Limbic-predominant, P < .01; Limbic-predominant > Mild, P < .05. (B) 
Bullseye plots displaying regional spread of white matter hyperintensity volumes. The 
concentric rings of the plot represent four equidistant layers of white matter (center = 
periventricular and outer layer = juxtacortical). (C) The slopes for MMSE scores over time 
as estimated by linear mixed models. Abbreviations: AD, Alzheimer’s disease; MMSE, 
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Mini-Mental State Examination; SUVR, Standardized uptake value ratio; PVC, partial 
volume corrected.
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.17
]
1.
88
 [1
.50
–2
.27
]
 
M
ed
ia
l
5.
09
 [3
.67
–6
.52
]§
3.
47
 [2
.20
–4
.74
]
3.
34
 [2
.47
–4
.21
]
3.
34
 [2
.02
–4
.65
]
 
Pe
rip
he
ra
l
1.
12
 [0
.79
–1
.46
]
1.
19
 [0
.78
–1
.60
]
1.
10
 [0
.81
–1
.38
]
1.
25
 [0
.78
–1
.71
]
N
OT
E.
 V
al
ue
s r
ep
re
se
nt
 m
ar
gi
na
l m
ea
n 
[9
5%
 co
nfi
de
nc
e 
in
te
rv
al
] w
hit
e m
att
er 
hy
pe
rin
te
ns
ity
 v
o
lu
m
es
 (m
L)
 af
ter
 co
rre
cti
on
 fo
r a
ge
, s
ex
, 
to
ta
l i
nt
ra
cr
an
ia
l v
o
lu
m
e,
 a
nd
 c
en
te
r. 
P 
v
al
ue
s a
re
 b
as
ed
 o
n 
W
al
d 
T-
te
st
s.
A
bb
re
v
ia
tio
n:
 A
D
, A
lz
he
im
er
’s
 d
ise
as
e.
*
Ty
pi
ca
l A
D
 >
 H
ip
po
ca
m
pa
l s
pa
rin
g 
A
D
, P
 
<
 .0
5.
† T
yp
ic
al
 A
D
 >
 m
ild
 a
tro
ph
y 
A
D
, P
 <
 
.
01
 &
 T
yp
ic
al
 A
D
 >
 H
ip
po
ca
m
pa
l s
pa
rin
g 
A
D
 a
nd
 L
im
bi
c-
pr
ed
om
in
an
t A
D
, P
 <
 
.
05
.
‡ T
yp
ic
al
 A
D
 >
 H
ip
po
ca
m
pa
l s
pa
rin
g 
A
D
 a
nd
 L
im
bi
c-
pr
ed
om
in
an
t A
D
, P
 <
 
.
01
 &
 T
yp
ic
al
 A
D
 >
 m
ild
 a
tro
ph
y 
A
D
, P
 <
 
.
05
.
§ T
yp
ic
al
 A
D
 >
 L
im
bi
c-
pr
ed
om
in
an
t A
D
, P
 <
 
.
05
.
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